Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928031 · ClinicalTrials.gov registry record
Long-term Data Collection for Subjects in MDX-010 Studies
A clinical trial of Metastatic Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 160
- Enrollment target
- 11
- Study locations
NCT00928031 is a study of Metastatic Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 160 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% higher). The trial reports 11 study locations across 9 states.
The verdict
NCT00928031, a study of Metastatic Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
- 11
- Study locations
Study Summary
The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
Conditions Studied
Study Locations (11)
California
- Pacific Shores Medical Group - Long Beach
- The Angeles Clinic and Research Institute - Los Angeles
- USC Norris Cancer Center - Los Angeles
Arizona
- Arizona Cancer Center - Tuscon
Florida
- University of Miami Sylvester Cancer Center - Miami
Indiana
- St. Francis Research Foundation - Beech Grove
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- NYU Cancer Institute - New York
North Carolina
- Carolinas Cancer Care - Charlotte
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928031
The ClinicalTrials.gov registry entry for NCT00928031 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT00928031 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00928031 about?
NCT00928031 is a clinical study titled "Long-term Data Collection for Subjects in MDX-010 Studies". The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
What is the current status of trial NCT00928031?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2007-06. Estimated completion is 2009-04.
What conditions does trial NCT00928031 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
Who is sponsoring clinical trial NCT00928031?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00928031 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.